Unravelling the suboptimal response ofTP53-mutated chronic lymphocytic leukaemia to ibrutinib-Reference-Cited by-同舟云学术

Unravelling the suboptimal response ofTP53-mutated chronic lymphocytic leukaemia to ibrutinib

Published:2018-10-18 Issue:3 Volume:184 Page:392-396
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Guarini Anna¹,Peragine Nadia²,Messina Monica²^ORCID,Marinelli Marilisa²,Ilari Caterina²,Cafforio Luciana²,Raponi Sara²^ORCID,Bonina Silvia²,Mariglia Paola²,Mauro Francesca R.²^ORCID,Gaidano Gianluca³,Del Giudice Ilaria²^ORCID,Foà Robin²

Affiliation:

1. Department of Molecular Medicine; “Sapienza” University; Rome Italy

2. Department of Cellular Biotechnologies and Haematology; “Sapienza” University; Rome Italy

3. Department of Translational Medicine; Amedeo Avogadro University of Eastern Piedmont; Novara Italy

Funder

Associazione Italiana per la Ricerca sul Cancro

Special Program Molecular Clinical Oncology

Ricerca Finalizzata

Ministry of Health

Progetti di Rilevante Interesse Nazionale

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.15613/fullpdf

Reference15 articles.

1. Cell-intrinsic determinants of ibrutinib-induced apoptosis in chronic lymphocytic leukemia;Amin;Clinical Cancer Research,2017

2. Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL;Brown;Leukemia,2017

3. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia;Burger;New England Journal of Medicine,2015

4. Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib;Burger;Journal of Clinical Investigation Insight,2017

5. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib;Byrd;Blood,2015

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tp53 disruptions: is there a marker of poor prognosis in chronic lymphoproliferative disorders?;BLOOD RESEARCH;2021-12-31

2. Treatment with ibrutinib does not induce a TP53 clonal evolution in chronic lymphocytic leukemia;Haematologica;2021-10-14

3. Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies;Blood;2021-09-30

4. Targeting the p53 Pathway in CLL: State of the Art and Future Perspectives;Cancers;2021-09-18

5. Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies;Frontiers in Oncology;2020-10-26